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Nucleoside analogs and non-nucleoside inhibitors of HIV-1 reverse transcriptase (RT) are now widely used to treat HIV infection (1) (2) (3) . The combined use of HIV RT and protease inhibitors has markedly improved the treatment of HIV infected patients, yet resistance of HIV-1 to anti-retroviral therapy remains a major cause of treatment failure (4, 5) .
The thiopurines mercaptopurine (MP) and thioguanine (TG) are widely used as antileukemic agents, targeting proliferating malignant cells with high DNA replication rates (6, 7) . 2Ј-Deoxy-6-thioguanosine 5Ј-triphosphate (dG S TP), the active metabolite of MP and TG, is known to be a good substrate for human DNA polymerases ␣, ␦, and ␥, with K m 's similar to those of natural substrates (8) . Incorporation of dG S into DNA leads to notable alterations in DNA properties, affecting interactions with several DNA binding proteins (9 -12) . Thiopurines have also been shown to have anti-viral effects against herpes simplex virus (13), influenza viruses (14) , and SV40 (15) , but anti-HIV effects have not been recognized and the mechanism(s) underlying the known anti-viral activities has not previously been elucidated.
Recently, we demonstrated that incorporation of deoxythioguanosine into the DNA strand of DNA-RNA heteroduplexes abrogates RNA hydrolysis by bacterial and mammalian RNase H (16) . These findings led us to postulate that thiopurine treatment of cells could reduce viral RNA cleavage, thereby inhibiting early stages of HIV replication. Here we report that deoxythioguanosine triphosphate is incorporated into DNA by HIV-1 RT, abrogating RNA cleavage by HIV-1 RNase H and producing significant anti-HIV effects in human lymphocytes.
MATERIALS AND METHODS

General reagents
All chemicals were of analytical or reagent grade and were used without further purification. All of the natural deoxyribonucleoside 5Ј-triphosphates (dNTPs) and the DNA oligonucleotide size markers (8 -32 mer) were purchased from Pharmacia Biotech (Peapack, NJ). [␥- 32 P] ATP was obtained from Amersham (Piscataway, NJ). The RNA oligonucleotide size markers were prepared by alkaline hydrolysis with piperidine (17) . Fresh human blood seronegative for HIV and hepatitis B virus (HBV) was obtained from the American Red Cross (Baltimore, MD). The lymphotropic clinical isolate HIV-1 ROJO was obtained from Southern Research Institute Co., Frederick, MD. Phytohemagglutinin was obtained from Sigma (St. Louis, MO) and recombinant IL-2 was from Amgen (San Francisco, CA). Tritiated thymidine triphosphate was obtained from New England Nuclear (Boston, MA).
Preparation of dG S TP
dG
S TP was prepared from 5Ј-DMT-3Ј-Bz-N2-phenylacetyl-2Ј-deoxyguanosine (Sigma) by consecutive treatment with thioacetic acid according to the previously published method (18) and subsequent phosphorylation with 2-chloro-4H-1,3,2-benzodioxaphosphorin-4-one (Fluka, Buchs, Switzerland) (19) . Deblocked product was dissolved in 2 M LiClO 4 and precipitated with acetone. The final purification was achieved by ion-exchange chromatography on a column (1ϫ30 cm) packed with Toyopearl DEAE-650M (Supelco, Bellefonte, PA) in a gradient of LiClO 4 (0 -0.2M) in 10 mM Tris-HClO 4 pH 7.0. The presence of a 6-thio group was confirmed by UV spectrum (maxϭ340 nm) and the presence of a triphosphate group was confirmed by activity of the product in the polymerization reaction catalyzed by Klenow fragment (9) .
RNA template and DNA primer preparations
The DNA oligonucleotides (18 and 20 mer primers) were synthesized by the Yale DNA synthesis facility and 5Ј radiolabeled with T4 polynucleotide kinase (New England Biolabs, Beverly, MA). The RNA oligonucleotide (49 mer, Fig. 1 ) was synthesized by in vitro transcription (MEGAscrip, Ambion) and 5Ј radiolabeled by dephosphorylation with shrimp alkaline phosphatase (Amersham), followed by phosphorylation with T4 polynucleotide kinase. Purity of the oligonucleotides was estimated by polyacrylamide gel electrophoresis (20% PAGE, 8 M urea).
The heteroduplexes R49/D20 and R49/D18 ( Fig. 1 ) were formed by annealing ϳ1:1.2 molar ratio of DNA primer and the corresponding RNA template at 90°C for 4 min and 50°C for 30 min. Oligonucleotide concentrations were determined spectrophotometrically. The following molar extinction coefficients (ε 260 ) were used for nucleotides: pA ϭ 15400; pT ϭ 9300; pU ϭ 8800; pC ϭ 7300, pG ϭ 11700; for pdG S , a molar extinction coefficient (ε 340 ) of 24800 was used (20) . The heteroduplexes were analyzed by nondenaturing PAGE (15%).
Preparation of HIV-1 RT
HIV-1 RT was purified as described previously (21, 22) . The protein concentration of purified HIV-1 RT was measured spectrophotometrically at 280 nm, using an extinction coefficient ε 280 ϭ 260,450 M Ϫ1 cm Ϫ1 . The concentration of active RT was determined as described previously with presteadystate burst experiments (21) , which gave burst amplitudes of 40%; the experiments described here were performed using the corrected active site concentration.
Kinetic analysis for single nucleotide incorporation into R49/D20 primer template by HIV-1 RT Rapid chemical quench experiments were performed as described previously with a KinTek Instruments Model RQF-3 rapid quench-flow apparatus at 37°C (21, 22) . Unless noted otherwise, all concentrations refer to the final concentration after mixing. In presteady-state burst experiments, HIV-1 RT (100 nM) and primer 32 P-labeled R49/D20 heteroduplex (300 nM) were preincubated on ice for 5 min in 50 mM Tris-HCl (pH 7.8), 50 mM NaCl. Polymerization was initiated at 37°C by the rapid addition of either dGTP (5-200 M) or dG S TP (10 -400 M) in buffer containing 10 mM MgCl 2 and the reactions were quenched at the indicated times with 0.3 M EDTA. Products were analyzed by PAGE.
Processive polymerization by HIV-1 RT on R49/D18 primer template
The processive polymerization was studied under steady-state condition in the presence of either dGTP or dG S TP, along with the other three dNTPs using primer 32 P-labeled R49/ D18 heteroduplex (Fig. 1) . The reaction conditions were similar to the single nucleotide incorporation studies, except for the following modifications: 10 nM (active site) HIV-1 RT and 1000 nM R49/D18 heteroduplexes used at a low concentration of dNTP (10 M) or 500 nM HIV-1 RT and 100 nM R49/D18 with a high concentration of dNTP including dG S TP (100 M) and 5 M dGTP. An aliquot of the reaction mixture was removed and manually quenched with 0.3 M EDTA at each time point. The reaction samples were analyzed as described below in Modeling and Parameter Estimation.
Effect of dG S inserts in DNA strand on HIV-1 RT RNase H activity
The processive polymerization was carried out under steadystate conditions in the presence of either dGTP or dG S TP with the other three dNTPs using 32 P-labeled RNA template of R49/D18 heteroduplex ( Fig. 1) . A aliquots of the reaction mixture was manually quenched at each time interval, and the reaction samples were analyzed as follows.
Modeling and parameter estimation
All samples from HIV-1 RT activity assays were analyzed by gel electrophoresis (20% PAGE, 8 M urea). The reaction products were quantified using a Bio-Rad GS525 Molecular Imager (Bio-Rad, Hercules, CA) and Molecular Imager software (Bio-Rad). Data were fitted by nonlinear regression using the program KaleidaGraph (version 3.09, Synergy Software). Data from burst experiments were fitted to a burst equation:
[product] ϭ A[1-exp(Ϫk obsd t)ϩk ss t], where A represents the amplitude of the burst that correlates with the concentration of enzyme in active form, k obsd is the observed first-order rate constant for dNTP incorporation, and k ss is the observed steady-state rate constant. The dissociation constant, K d , for dNTP binding to the complex of RT and 20/49 heteroduplex is calculated by fitting the data into the following hyperbolic equation:
, where k pol is the maximum rate of dNTP incorporation, [dNTP] is the corresponding concentration of dNTP, and K d is the equilibrium dissociation constant for the interaction of dNTP with the enzyme-DNA complex. The mathematical model was fit to data on the cleavage of R49/D49G or R49/D49G S heteroduplexes using maximum likelihood fitting techniques via the ADAPT II program (23) .
Transduction of HeLa cells with HIV-based gene transfer vector
HeLa cells were treated with MP or TG freshly dissolved in 1:1 sterile H 2 O:DMSO to make a 10 mM stock solution (final concentration in experiments 0.1-10 M). Cells were treated with MP or TG added either 16 -20 h before transduction or simultaneously with the vector, essentially as described previously (24, 25) . Briefly, HeLa cells (2ϫ10 4 per well) were plated on 6-well tissue culture dishes the day before transduction (MOIϭ0.2 and 0.6) with concentrated RtatpEGFP vector supernatant. Cells were harvested 36 h after transduction and analyzed by flow cytometry using a FACScalibur instrument (BD). Data were collected and analyzed using CellQuest software (BD). Percent inhibition was determined as the difference between transduction with and without the addition of MP or TG at the two different vector concentrations indicated above. To ensure that EGFP expression was due to effective transduction with the lentivirus vector, samples of HeLa cells were also incubated with 5-50 M zidovudine (AZT) for 30 min before addition of vector. Under these conditions, AZT reduced transduction efficiency by 95% (data not shown) (24, 25) .
Anti-HIV activity of MP and TG
Experiments to assess the antiviral and cytotoxic effects of thiopurines in human peripheral blood mononuclear cells (PBMC) infected with HIV-1 ROJO were performed by Southern Research Institute, as follows. Fresh human PBMC were isolated from blood drawn from HIV and HBV seronegative donors, as determined by the American Red Cross. PBMC were isolated by Ficoll-Hypaque density centrifugation and infected with a clinical isolate HIV-1 ROJO at an MOI of 0.1, either simultaneously or 20 h after treatment with six semi-log dilutions of thioguanine (0 -200 M). Antiviral activity and cellular toxicity were assessed 6 days postinfection by reverse transcriptase activity assay (26) and 2,3-bis[2-methoxy-4-nitro-5-silfophenil]2H-tetrazolium-5-carboxanilide staining (27) . The difference between the anti-HIV effect and cytotoxicity was evaluated by the Wilcoxon matched pairs test.
Analysis of drug combination assay was performed as described (27) with statistical evaluations performed according to the methods of Prichard and Shipman (28) . 
RESULTS
dG S TP incorporation by HIV-1 RT
The maximum rate of incorporation (k pol ), equilibrium dissociation constant (K d ), incorporation efficiency (k pol /K d ), and the linear steady-state rate (k ss ) for dGTP and dG S TP from presteady-state burst experiments with defined R49/D20 heteroduplex are summarized in Table 1 .
S TP into a DNA strand of R49/D20 is shown in Fig. 2 , indicating that dG S TP is a reasonably good substrate for HIV-1 RT.
Processive polymerization by HIV-1 RT on R49/D18 heteroduplex
The processive primer elongation using dG S TP vs. dGTP in R49/D18 heteroduplex ( Fig. 1) was studied under steady-state conditions at concentrations of dNTP ranging from 10 M to 100 M. For the natural substrate dGTP, the majority of elongated products were in the fully extended form (DNA 49 mer) after 40 min of incubation. In the presence of the dG S TP analog, however, formation of the fully extended product was significantly less: most of the product formed corresponded to a DNA 20 mer (data not shown). Processive elongation of the 18 mer DNA primers occurred with similar efficiency in the presence of 100 M dG S TP or 5 M dGTP (Fig. 3) . The presence of dG S in the DNA strand was confirmed by enzymatic hydrolysis to nucleosides, followed by HPLC analysis, as we have previously described (16) . The nucleoside ratio in D49G S (dA/dG/dT/dC/dG S ) was 11/6/11/12/3, close to the theoretically calculated ratio of 11/6/12/ 15/5.
RNA degradation within DNA/RNA heteroduplex by RNase H activity of HIV-1 RT
The cleavage of RNA within the DNA/RNA heteroduplex by the RNase H activity of HIV-1 RT was characterized in 5Ј-32 P-RNA-labeled R49/D49 or 5Ј-32 P-RNA-labeled R49/D49G S heteroduplexes after RT polymerization with dGTP or dG S TP (Fig. 4) . Incorporation of dG S into R49/DG S 49 by HIV-1 RT polymerization ( Fig. 1) Fig. 4, bottom panel) .
Inhibition of RtatpEGFP transduction in the presence of MP or TG
Incubation of HeLa cells with MP or TG for 16 -20 h before addition of the HIV-based vector, with EGFP expression analyzed 36 h later, resulted in 50% inhibition by 1.0 M MP or 0.1-1 M TG at MOI ϭ 0.2 (Fig.  5B, D) . Inhibition was also evident at a higher level of infection (MOIϭ0.6), but less than that observed at the lower level of infection (inhibition for 1.0 M TGϭ32% and for 10 M MPϭ43%; Fig. 5C, E) .
Anti-HIV effects in cell cultures
Significant anti-HIV effects (decrease in RT activity) were evident in HIV-1-infected peripheral blood lymphocytes pretreated with thioguanine (Fig. 6, filled  symbols: IC 50 ϭ0.0346 M, IC 95 ϭ15.4 M) . TG was significantly less toxic to donor lymphocytes, as depicted in Fig. 6 (open symbols: TC 50 Ͼ200 M). The difference between the anti-retroviral activity and cytotoxicity curves (Fig. 6 ) was statistically significant (Wilcoxon matched pairs test, PϽ0.000005).
The activity of TG in combination with AZT revealed evidence of at least additive interactions across the entire range of concentration tested, with evidence of synergy at low concentrations (synergy volumeϭ19 M 2 %). There was no evidence of synergetic cytotoxicity in uninfected PBMCs at all combined concentrations of TG and AZT examined. In fact, TG was less toxic to host cells when given with AZT than without (data not shown). 
DISCUSSION
Using the model system depicted in Fig. 1 , we provide the first evidence that dG s TP is incorporated into viral DNA by the polymerase function of HIV-1 RT. The diagnostic burst phase observed in presteady-state experiments indicates that HIV-1 RT recognizes and incorporates dG S TP in a manner similar to that of natural dNTPs, whereas binding affinity (K d ) of dG S TP (110Ϯ30 M) for the enzyme-DNA complex is ϳthree-fold weaker than that of dGTP (35Ϯ4 M). Experiments with 5Ј-32 P-labeled DNA primers showed that both dGTP and dG S TP were incorporated into DNA of R49/D20 heteroduplex, although the maximum rate of incorporation (k pol ) and the incorporation efficacy (k pol /K d ) were lower for dG S TP (Table 1 ). The single nucleotide incorporation studies of dGTP vs. dG S TP indicate that the rate of incorporation for 5 M dGTP is similar to the rate for 100 M dG S TP (Fig. 2) . This is consistent with DNA synthesis stalling at the site where the next correct incoming dNTP is dG S TP opposite a template cytosine. Accumulation of the full-length cDNA product (D49) occurred in the presence of either dGTP or dG S TP (Fig. 3) , clearly demonstrating that similar to bacterial and mammalian DNA polymerases (8), the RNA-dependent DNA polymerase of HIV-1 efficiently uses dG S TP for viral cDNA synthesis. Cleavage of viral RNA by the RNase H function of HIV-1 RT, essential for early stages of HIV replication, is accomplished through two different modes (29, 30) : one polymerase dependent and the other polymerase independent (31). In our model (5Ј-P 32 -labeled 49 mer oligoribonucleotide template), the primary polymerase-dependent RNaseH cleavage results in formation of 17 and 18 mer RNA fragments (Figs. 1 and 4) . The secondary RNase H cleavage (29) leads to further degradation of the 17-18 mer RNA fragments to shorter RNA fragments (15-9 mer RNA, Fig. 4) . The linear steady-state rate parameters (k 49 ) for cleavage of the R49 template document that the rates of hydrolysis of R49 by the primary polymerase-dependent RNaseH cleavage are comparable for both heteroduplexes R49/ D49 and R49/DG S 49, because there is no dG S incorporated close to this position (Fig. 1) . Shorter cleavage products are thereafter formed due to the exonuclease activity of RNase H (second mode), which acts progressively toward the 5Ј-end of the RNA (30) . The cleavage of 18/17 mers for R49/DG S 49 was threefold slower than for R49/D49 (Fig. 4, bottom panel) . The pattern of short hydrolysis products was markedly altered at the sites opposite dG S in the DNA strand of the heteroduplex (no RNA fragments shorter that 12 mer was found for R49/DG S 49), indicating that hydrolysis of the RNA strand of the heteroduplex by exonuclease activity of HIV-1 RNase H is largely abolished at positions close to dG S inserts. This is consistent with our previous findings that the rate of hydrolysis of a heteroduplex by bacterial or mammalian RNase H is decreased within 2-3 nucleotides of the dG S incorporated into the deoxy strand of the heteroduplex (16) . The effect of MP and TG on the initial phases of the HIV replication cycle (using RtatpEGFP, Fig. 5 ) indicate that the targets of anti-HIV effects of TG are events occurring no later than transcription of viral RNA from the proviral DNA, consistent with the data documenting inhibition of RNA cleavage by HIV RNase H. In contrast to existing RT-targeting drugs that directly inhibit the polymerase function or bind to the RNase H-catalyzing center of RT, incorporation of dG S into the minus strand of viral DNA creates poor RNase H substrates, thereby abrogating subsequent hydrolysis of RNA in the RNA/G S DNA hybrid, representing a novel strategy for inhibiting retroviral replication.
As shown in Fig. 6 , anti-HIV effects were evident in PBMC treated with thioguanine 20 h before viral infection, reaching a maximum of 98% inhibition at Ͼ10 M TG (filled symbols: IC 50 ϭ0.0346 M, IC 95 ϭ15.4 M). Cytotoxicity of TG on donor lymphocytes (Fig. 6 , TC 50 Ͼ200 M) revealed a statistically significant difference between the anti-HIV and cytotoxicity curves (P Ͻ 0.000005). These concentrations are well within the usual plasma and cerebrospinal fluid concentrations achieved after oral and intravenous administration of MP in humans (0.2-4 M) (32, 33) . In slowly dividing cells, the most active DNA synthesis is likely that of proviral cDNA; thus, the major thioguanylated DNA would be viral DNA, consistent with greater antiviral activity than cytotoxicity. TG treatment simultaneously with infection of PBMC (i.e., 0 h pretreatment with TG) also had antiviral effects (IC 50 ϭ1.48 M, data not shown); the higher IC 50 is consistent with the requirement for metabolic activation of TG before its effects are evident. When evaluated in combination with AZT, there was evidence of at least additive interactions across the entire concentration range tested, with evidence of synergy at TG ϭ 0.195 M and AZT 3.25 nM (synergy volumeϭ19 M 2 %). Evidence of additive antiviral activity and the absence of additive cytotoxicity of TG and AZT to host lymphocytes indicates that TG warrants further evaluation as a component of antiviral chemotherapy.
These experiments establish that incorporation of dG S TP affects both steps of viral replication-DNA polymerization and RNA cleavage; therefore, thiopurines represent a new class of agents with anti-retroviral activity. The currently available non-nucleosides inhibitors of HIV-1 RT interfere with RNase H (34) and polymerase (35) functions by binding a specific region of the p66 subunit of HIV-1 RT in a hydrophobic pocket of the palm domain, and mutations in this binding site have been shown to confer HIV-1 resistance to these agents. Because thiopurines inhibit RNaseH function by modifying its DNA-RNA substrate, and not by directly binding HIV RT, its anti-HIV activity should not be impaired by these HIV-RT mutations. Thus, the present work establishes that thiopurine medications, which have been in clinical use for almost 50 years, possess novel anti-retroviral effects that may complement contemporary agents used to treat HIV infected patients. (27) . Each curve represents mean (Ϯsd) from three replicate experiments (PϽ0.000005 by Wilcoxon matched pairs test).
